ZnT-5 deficiency-related bone impacts are seen in mice [96], and if this can be proven in humans, it may be useful to stratify men at diagnoses for prostate cancer management protocols towards minimizing bone-impacting ADT therapies [98,213,214] which will be needed to manage advance prostate cancer. This evidence concerns the gene SLC30A5 and prostate cancer.